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Innovation in healthcare is a central way of coping with the changes affecting the healthcare 
system through the megatrends of demographic change, digitalization as well as the opportuni-
ties in the life-sciences sector and the “-omics” subjects. Due to the multiple facets of the topic, 
research on innovation in healthcare is diverse and draws insights from systems theory, ma-
nagement theory, human resources, innovation and change management. While the literature 
on innovation in healthcare has grown steadily in the last 20 years and publications on phar-
maceutical and medical device innovation, health technology assessment strategies, or digital 
innovations have increased significantly, other areas such as sectoral health innovation systems, 
the creation and implementation of innovation in hospitals still remain fairly uncharted. Apply-
ing established concepts such as systems of innovation theory, mass customization theory or 
management of employee involvement in innovation activities to the healthcare sector provides 
new insights into a field that is often considered a “blackbox”. This thesis adds to the topic in 
three essays, each focusing on a different aspect and depth level ranging from a macro perspecti-
ve on healthcare innovation on a global scale to a meso level perspective on the implementation 
of personalized medicine in one country and putting a micro lens on innovation activities of 
hospital staff. The aim of this thesis is to provide an overview for researchers, policy makers and 
healthcare stakeholders about current developments, propose tools for measuring innovation 
and allow for benchmarking the current status quo in healthcare in order to foster new and in-
novative developments.
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1. Introduction  
The healthcare system in the western world is a complex sector with a strong impact 
on social welfare (Held, 2016; Porter & Teisberg, 2006). It is multifaceted and 
encompasses a multitude of stakeholders, a rapidly changing technological 
environment and the need to balance excellent health outcomes with reasonable cost of 
care. The demographics of society are changing: the global population is growing, 
society is aging within the western world and developed countries face a net positive 
immigration. Digital transformation is set to change the world through smart devices 
and infrastructures, machine learning, artificial intelligence, automation and 
connectivity, impacting all industry sectors and the life of patients, practitioners, 
healthcare stakeholder and everyday people alike. Through the improved access to 
(medical) knowledge within the global knowledge society, citizens are able to learn 
about prevention of diseases. Patients are becoming better informed about their 
illnesses and treatment options. As a consequence they often demand the use of the 
best available technology and the provision of higher service levels. Advancements in 
life sciences and the “-omics” subjects have the potential to allow for more targeted 
treatments with fewer side effects and better health outcomes. The combination of all 
these effects leads to an increased need for innovation within the healthcare sector that 
required the attention of all stakeholders alike (Roncarolo, Boivin, Denis, Hébert, & 
Lehoux, 2017). This development poses a very relevant and interesting topic for 
researchers and thus, the research on innovation in healthcare has gained importance in 
the last decades (Conger, 2016; Djellal & Gallouj, 2007; Dzau, Asch, Hannaford, 
Aggarwal, & Pugh, 2017; Kelly & Young, 2017; Porter & Guth, 2012; Ramlogan & 
Consoli, 2007; Thune & Mina, 2016).  
Due to the multiple facets of the topic, research on innovation in healthcare is diverse 
and draws insights from systems theory, management theory, human resources, 
innovation and change management. In general, research on innovation in healthcare 




1. General literature reviews (Boaz, Baeza, & Fraser, 2011; Djellal & Gallouj, 
2007; Länsisalmi, Kivimäki, Aalto, & Ruoranen, 2006; Thune & Mina, 2016) 
2. Healthcare systems (e.g. (Braithwaite et al., 2017; Porter, 2009; Starfield & Shi, 
2002)  
a. Single country studies (developed and emerging countries, e.g. (Caliari 
& Ruiz, 2011; Myllyoja et al., 2016; OECD, 2011; Porter & Guth, 2012; 
Simou & Koutsogeorgou, 2014) 
b. Country comparisons (e.g. Calltorp, 1999)  
c. System transformation and innovation policy (e.g. (Eiff, 2016; 
Mazzucato & Roy, 2017; Porter, 2010; Sobrio & Keller, 2007) 
3. Health Innovation Systems (Buttigieg & Gauci, 2015; Donaldson & Mohr, 
2001; Iyawa, Herselman, & Botha, 2016; Martin, 2013) 
a. Regional health innovation systems (Jonsson, 2009; Larisch, Amer-
Wåhlin, & Hidefjäll, 2016) 
b. Single technology / sectoral innovation (Consoli & Ramlogan, 2012; 
Metcalfe, James, & Mina, 2005; Ramlogan & Consoli, 2007) 
c. Public health innovation (Béland, 2010; Conger, 2016; Lander, 2016; 
Marmor, Freeman, & Okma, 2005; Marmor & Wendt, 2012) 
4. Objects of innovation in healthcare (e.g. Amshoff, 2010) 
a. Service innovation (e.g. (Bessant & Maher, 2009; Ciasullo & Cosimato, 
2017; Fox, Gardner, & Osborne, 2015; Keller, Edenius, & Lindblad, 
2013; Pfannstiel & Rasche, 2017) 
b. (Medical) Device innovation (e.g. (Callea, Cavallo, Tarricone, & 
Torbica, 2017);(Galbrun & Kijima, 2010; Gelijns et al., 2013; Hermelin, 
Dahlström, & Smas, 2014; Skinner & Staiger, 2015) 
c. Innovation for pharmaceuticals (e.g. (Bianchi, Cavaliere, Chiaroni, 
Frattini, & Chiesa, 2011; Chiaroni, Chiesa, & Frattini, 2009; Hippel, 
DeMonaco, & de Jong, Jeroen P. J., 2016; Hughes & Wareham, 2010; 




d. Hospital and hospital management innovation (e.g.(Albach, Meffert, 
Pinkwart, Reichwald, & Eiff, 2016), (Bose, 2003; Braithwaite, Vining, 
& Lazarus, 1994; Debatin, Goyen, & Schmitz, 2006; Goes & Park, 1997; 
Salge & Vera, 2009) 
e. Digital health innovation (e.g. (AlMarshedi, Wills, & Ranchhod, 2016; 
Ramtohul, 2016) 
i. eHealth (incl. telemedicine, e.g. (Black et al., 2011; Chen, Wen, 
& Yang, 2014; Eysenbach, 2001; Hordern, Georgiou, Whetton, & 
Prgomet, 2011; Peters, Blohm, & Leimeister, 2015; Valerie, 
Giesen, Jansen, & Klokgieters, 2010) 
ii. mHealth (e.g. (Dale, Dobson, Whittaker, & Maddison, 2016; 
Hamine, Gerth-Guyette, Faulx, Green, & Ginsburg, 2015; Head, 
Noar, Iannarino, & Grant Harrington, 2013; Lazakidou, 2016; 
Ventola, 2014) 
iii. Electronic health records (e.g. Hillestad et al., 2005) 
5. Sources of innovation in healthcare (e.g. (Herzlinger, 2006; Leydesdorff, 
Rotolo, & Rafols, 2012; Nelson, Buterbaugh, Perl, & Gelijns, 2011) 
a. Open innovation and collaboration (e.g. (Bullinger, Rass, Adamczyk, 
Moeslein, & Sohn, 2012; Gelijns, Annetine, Thier, SO, 2002; Hartweg, 
Kaestner, Lohmann, Proff, & Wessels, 2015b; Nembhard, 2009; 
Reinhardt, Bullinger, & Gurtner, 2015; van den Broek, Boselie, & 
Paauwe, 2017)  
b. User-led innovation  (e.g. (Oliveira & Canhho, 2014) 
i. Patients (e.g. (Fidelis, Zejnilovic, & Oliveira, 2014; habicht, 
Oliveira, & Shcherbatiuk, 2012; McColl-Kennedy et al., 2017; 
Svensson & Hartmann, 2018; Swan, 2009; Trigo, 2016) 
ii. Practitioners and management (e.g. (Amo, 2006; Birken, Lee, & 
Weiner, 2012; Chen, Lee, Parboteeah, Lai, & Chung, 2014; 
Kajamaa, 2015; Schultz, Schreyoegg, & Reitzenstein, 2013; 




iii. Employees (e.g. (Fottler, Blair, Whitehead, Laus, & Savage, 
1989; Kokkinen & Konu, 2012; Lahtinen, Aaltonen, Järvinen, 
Teittinen, & Pirttimäki, 2017; O'Donoghue, Stanton, & Bartram, 
2011; Thune & Gulbrandsen, 2016) 
c. Technological trajectories (Lehoux, Miller, Daudelin, & Denis, 2017; 
Mina, Ramlogan, Tampubolon, & Metcalfe, 2007; Ramlogan, Mina, 
Tampubolon, & Metcalfe, 2007; Thrane, Blaabjerg, & Møller, 2010) 
6. Assessment of innovation in healthcare (Burgess, 2012; Cucciniello & Nasi, 
2013; Jacobs et al., 2017; Klazinga, Fischer, & Asbroek, 2011) 
a. Cost and quality (Chandra & Skinner, 2011; DiMasi, Hansen, & 
Grabowski, 2003; Goyen & Debatin, 2009; Kairy, Lehoux, Vincent, & 
Visintin, 2009; Wahlster, Goetghebeur, Kriza, Niederlander, & 
Kolominsky-Rabas, 2015; Wang et al., 2003) 
b. Diffusion (Cain & Mittman, 2002; Chaudoir, Dugan, & Barr, 2013; 
Ciani et al., 2016; Fitzgerald, Ferlie, Wood, & Hawkins, 2002)  
c. Health technology assessment and management (Brower, 2003; Hartz & 
John, 2009; Lebioda, Gasche, Dippel, Theobald, & Plantör, 2014; 
Schreyögg, Bäumler, & Busse, 2009) 
7. Healthcare innovation management processes (Granig, Gabriel, Stadtschreiber, 
& Pertl, 2011; Minvielle, Waelli, Sicotte, & Kimberly, 2014) 
a. Within hospitals (Chiocchio & Richer, 2015; Djellal & Gallouj, 2005; 
Ivan Su, Gammelgaard, & Yang, 2011; Labitzke, Svoboda, & Schultz, 
2014; Nilsson & Sandoff, 2016; Salge, 2012; Schultz, Zippel-Schultz, & 
Salomo, 2012) 
b. Within the pharmaceutical industry (e.g. (Gassmann & Reepmeyer, 
2005; Rosenberg-Yunger, Daar, Singer, & Martin, 2008) 
While the literature on innovation in healthcare has grown steadily in the last 20 years 
and publications on pharmaceutical and medical device innovation, health technology 
assessment strategies, or digital innovations have increased significantly, other areas 




implementation of innovation in hospitals still remain fairly uncharted. Calls have 
been placed to e.g. analyze the link between health policy and innovation policy, the 
“boundaryless hospital” (Albach et al., 2016; Braithwaite et al., 1994) and the 
relationship between hospital resources, clinical practice and innovation or micro-level 
analyses of innovation and hospital practitioners.  
2. The purpose of a multi-level analysis in the field of healthcare 
innovation 
 
Innovation in healthcare can be viewed through a multitude of lenses at different depth 
levels. In order to tackle the aforementioned challenges that the healthcare systems in 
the (western) world face, policy makers, healthcare managers and other stakeholders 
within the healthcare system need to be informed about the current status of innovation 
production and commercialization in their specific jurisdiction and how it compares at 
the regional, national and global level in order to learn and benefit from winning 
formulas and mistakes made before by other participants. Further, they need to know 
how innovation in the sector occurs, how to define whether an innovation is beneficial 
as well as how to implement and measure the results of successful innovation in their 
surroundings.  
This thesis uses well-established concepts such as the theory behind national and 
sectoral innovation systems, mass customization and employee involvement and 
applies these concepts to the healthcare system. In order to provide comprehensive 
insights into the research topic, this thesis analyzes the topic of innovation in 
healthcare in three essays. These essays provide a macro, a meso and a micro 
perspective, each targeting a specific field.  
Overall, this thesis adds to the understanding of the “blackbox” innovation in 





(1) Measurement of healthcare innovation and global benchmarking 
By applying a multi-indicator approach to measure innovation in healthcare we divert 
from the conventional way of only considering patents or scientific publications as 
innovation metrics and provide a more comprehensive way of benchmarking 
innovative capacity, not only for the sectoral case healthcare, but also for the national 
innovation system.  
(2) Transfer of the NIS concept to sub-national entity NHIS   
By transferring the established concepts of NIS and NIC to the sectoral case 
“healthcare”, this thesis contributes to a better understanding of sub-national entities, 
such as specific industrial sectors, which “are becoming, or have already become, 
more important than the nation-state” (Freeman, 1998, p. 3; Lundvall, 2007) 
(3) Guidance on the creation and implementation of complex innovations in the 
healthcare system 
By applying the established concepts of mass-customization and employee 
involvement in innovation processes to the healthcare sector and thus diving deeply 
into the implementation of innovation in the healthcare sector, this dissertation 
showcases new insights into how public entities such as hospitals can learn from 
industry in order to improve their service delivery, provide a more targeted customer 
experience and improve employee satisfaction and retention in a highly competitive 
market for talent.  
The results of this thesis target the following stakeholders:  
The multi-indicator approach provides a new and improved way of measuring 
innovation in healthcare for researchers and thus sheds light into healthcare 
innovation. The clear distinction between NIS and NHIS provides significant 




Health policy makers benefit from the global benchmarking of healthcare systems and 
the deeper understanding of innovation dynamics in the healthcare sector, which are 
needed for more targeted health innovation policy initiatives. 
Finally, hospital management gains insights into factors that foster innovative 
activities amongst employees and can use those to improve patient care and hospital 
efficiency. Further, the derived readiness assessment model allows for targeted 
measures to improve innovation implementation success rates.   
3. The scientific contribution of this doctoral thesis 
This dissertation consists of three studies on innovation management in healthcare, 
each approaching the topic on a different level. An overview of the papers, their 
authorship, contribution and status of publication is provided in Table 1.  
The first article transfers the methodology of national innovative capacity to the 
healthcare sector and provides a macro-level view on the innovative output of the 
OECD healthcare systems. The second paper takes a meso perspective on one 
innovation system and provides an overview of success and readiness assessment 
factors for adopting the new concept of personalized medicine within the German 
healthcare system. The third paper focuses on the hospital and the involvement of 
employees in the innovation process. Overall, this thesis aims to provide insights into 
the interplay of different success factors in the change process that is underway within 





 Article 1 – Macro level Article 2 – Meso level Article 3 – Micro level 
Title National Health Innovation 
Systems: Clustering the 
OECD countries by 
innovative output in 
healthcare using a multi- 
indicator approach 
Adopting a Mass 
Customization Approach to 
Implement Personalized 
Medicine in German 
Hospitals 
Employee involvement in 
innovation activities in 
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3.1 National Health Innovation Systems: Clustering the OECD countries by 
innovative output in healthcare using a multi-indicator approach 
 Study significance: Innovation systems research distinguishes national, 
regional, technological and sectoral innovation systems. The healthcare 
innovation system can be classified as a sectoral innovation system. Despite the 
high importance of innovation for the provision of high-quality and cost-
effective care and its prominent role for global competitiveness, HISs have 
rarely been analyzed from a systems perspective. Moreover, there are only a 
few papers that have studied HISs in general and the determinants of innovative 
output in this field in particular in the last decades. This paper allows for a first 
comparison of innovative output in healthcare between countries and reveals a 
strong difference between the innovation output of a nation as a whole and 
healthcare as a specific sector. It answers the following research questions: (1) 
Can countries be grouped by their innovation output in healthcare and do those 
groups differ in factors describing the healthcare system? and (2) Do countries 
with strong national innovation systems also have strong national health 
innovation systems and vice versa? Moreover, it provides a measurement 
approach for the output of sectoral innovation systems through a multi-indicator 
approach and thus enables a more comprehensive view on sectoral innovation 
systems compared to previously used metrics.  Finally, it sheds light on a 
sectoral innovation system that has not yet been subject of an in-depth analysis.  
 Methodological approach: There is little empirical literature that provides 
comparisons of sectoral innovation systems amongst different countries, 
especially focusing on healthcare. We therefore performed a cluster analysis of 
the OECD countries (excluding Estonia, Iceland, Latvia, Luxembourg and 
Slovenia due to a lack of data in one or more of the output variables) in order to 
group countries by their innovative output in healthcare. We measured 
innovative output through a multi-indicator approach distinguishing knowledge 
production and knowledge commercialization variables. We further provide 




describe the health system of a country. The analysis is based on a data set of 14 
variables for each country for the years 1995-2014, whereby the cluster analysis 
uses data of 2012 (the most current year for which data was available for the 
majority of the countries included in the study). Though cluster analysis is a 
common method within national innovation systems and health system 
research, we are one of the first to apply the methodology to NHIS.  
 Main findings: The results show a two-to-nine cluster salutation with the four-
cluster solution producing the most interpretable results. The clusters strongly 
differ in their innovation output in healthcare. An overview of the cluster 
affiliation is provided in Table 2. 
Cluster A Cluster B Cluster C Cluster D  
Czech Republic Japan Australia Switzerland 
Portugal South Korea New Zealand Denmark 
Germany Hungary Israel Norway 
France Poland United States The Netherlands 
Italy Slovak Republic Canada Sweden 
Greece Turkey Austria  
Spain Chile United Kingdom  
 Mexico Ireland  
  Belgium   
  Finland  
 Table 2 – Four cluster solution (Proksch, Busch-Casler, Haberstroh, & Pinkwart,  
      2019) 
Cluster D ranks first in all variables other than patent output and is thus 
classified as the most innovative cluster.  Cluster C ranks first in patent output 
and second in the remaining variables. Cluster B ranks second in patent output 
and ranks last in all other variables. Cluster A has the weakest patent output and 
ranks third in all other variables. We further performed a cluster analysis using 
the same output variables but including all industries. The results show that 
NHIS differ from NIS. Having a strong national innovation system does not 
indicate a strong national health innovation system or vice versa.  
 Scientific / practical value: This research adds to the literature on innovation in 
healthcare, on national and sectoral innovation systems. We demonstrate that 
innovative output in healthcare differs among countries and that it allows for 




picture of healthcare innovation. Further, the resulting NHIS clusters differ 
from the NIS clusters when using the same indicators for the whole industry. 
We provide valuable insights for policy makers and policy researchers as 
sectoral innovation systems and specifically healthcare innovation systems are 
an important issue in political discussions. Our work provides a basis for 
assessing a country’s inputs and measures to boost innovation and facilitate 
cost-effective care. It shows that innovation in healthcare needs to be assessed 
more comprehensively, e.g. through considering specific factors such as the 
level of digitalization.   
 Areas of improvement: Measuring the innovative output in healthcare along the 
previously described four variables may not encompass all innovations. Process 
innovation in particular is hard to measure. Additionally, some healthcare 
innovations may not be patentable and may thus be partially excluded from our 
analysis.  The descriptive variables serve as a first indicator for characterizing 
the NHIS clusters. However, they may not encompass all relevant variables, as 
healthcare with its related regulations and financing is a complex system with 
diverse indicators and systems definitions.  
3.2 Adopting a mass customization approach to implement personalized 
medicine in German hospitals 
 Study significance: Patient demand for individually adjusted treatment and 
medical service experience has increased over the last years (Hartweg, 
Kaestner, Lohmann, Proff, & Wessels, 2015a) and hospitals have to customize 
their offerings accordingly. Personalized Medicine (PM) is an emerging 
concept which allows even more tailored treatments for patients based on 
extensive pre-treatment diagnostics and developments in the “-omics” subjects. 
Implementing PM in hospitals, however, poses a challenge. Using learnings 
from the established concept of mass customization (MC) may be a beneficial 
for implementing PM in hospitals. This paper is one of the first to examine the 




for implementing PM in hospitals. It answers the following research questions: 
(1) Is it beneficial to apply the concept of MC to hospitals in the context of 
PM?; (2) What are potential success factors?; (3) What is the status of PM 
implementation in Germany?; and (4) What are the implications for PM in 
German hospitals? It further provides insights into the current status of PM 
implementation within the German HIS.  
 Methodological approach: RQ 1 and RQ 2 are answered by applying the MC 
framework of (Broekhuizen & Alsem, 2000) to PM through a comprehensive 
literature review in order to assess whether the model is applicable to PM. The 
literature search was conducted through EBSCO and Google Scholar with 
“Personalized medicine” and “concept” as keywords. Overall, 70 papers 
published between 1999 and 2016 were reviewed in the literature analysis and 
statements matched to the categories proposed by (Broekhuizen & Alsem, 
2000). In order to provide insights for RQ 3 and 4, ten semi-structured expert 
interviews were conducted to get an initial overview and create a basis for 
further analysis. Interviews were conducted with experts from the main 
stakeholder groups: physician, hospital management, special PM center, the 
medical technology industry, pharmaceutical industry, medical IT industry, 
health insurance sector and academia. The interviews were conducted in 
German, taped, transcribed and coded through qualitative content analysis. 
Quotes presented in the findings were translated into English.   
 Main findings: Both, the results of the literature analysis and the interviews, 
indicate that the success and readiness factors proposed by Broekhuizen & 
Alsem (2002) may be beneficial for the implementation of PM in hospital. 
However, some adaptions may be required due to the specific nature of the 
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Figure 1 – Model of success factor PM readiness assessment (taken from Busch, 2016) 
 Scientific / practical value: This research adds to the literature on innovation in 
hospitals and the German sectoral innovation system. It demonstrates that the 
proposed success and readiness factors for MC can be transferred to PM 
implementation in hospitals with minor adaptions of the model due to the 
specific nature of the HIS. It further provides practitioners a tool for assessing 
their hospitals’ PM readiness and allows them to take measures to tackle the 
upcoming challenge of PM and its implementation. Finally, it provides 
practitioners with insights into the status of PM and its implementation in the 
German HIS. 
 Areas of improvement: Within the literature review, research results may have 
been neglected due to the vast amount of PM literature. The interview sampling 
was purposive. It represents only a small fraction of the relevant stakeholders 
and can only provide a contemporary snapshot of stakeholder opinions. As with 
qualitative research, the results of this paper cannot be generalized. Thus, 
additional quantitative research, e.g. an empirical study of the different 




insights. Additionally, the derived model of PM success factors has not been 
tested in a quantitative study, which may be an interesting future research 
opportunity.  
3.3 Employee involvement in innovation activities in hospitals: how perception 
matters 
 
 Study significance: Innovation has become ever more important for hospitals 
(Porter & Teisberg, 2006) with continuous calls for research into the subject of 
innovation creation, implementation and dissemination (Thune & Mina, 2016). 
Employees are a very important source of innovation, especially within a 
service (co-creation) environment (Bessant & Moeslein, 2011; Schweisfurth & 
Herstatt, 2016). (Perceived) high employee involvement has been shown to be 
beneficial along all steps of the innovation process (Abu El-Ella, Stoetzel, 
Bessant, & Pinkwart, 2013; Bessant, 2003). Perceived involvement, however, 
has not been studied extensively within the healthcare sector.  This study aims 
to answer the following research questions: (1) “How do different employee 
groups perceive their involvement in the innovation process and their 
interaction with other employee groups?” and (2) “How does this perception 
influence the innovation output?”  
This paper adds to the literature in the following respects: (a) showcasing 
perceived involvement in innovation activities and perceived between-group  
interactions within a hospital department, (b) deriving propositions for hospital 
management on how to foster innovative behavior among employees and (c) 
create a base case for management comparison.  
 Methodological approach: We use a qualitative single case study approach with 
theoretical and purposive sampling of a university-linked hospital with a 
baseline of innovation activities. We introduced the project to the head of the 
department, who facilitated introductions to some participants, but was 
unavailable for an interview. We performed 11 episodic interviews in German 




administration, medical technology management, laboratory staff, 
pharmacologists, and administrative staff). We further used publicly available 
data such as press coverage and annual reports to triangulate the results. All 
data was coded. We used a qualitative content analysis procedure with 
deductive category application.  
 Main findings: We found that all stakeholder groups are involved in innovation 
activities; however, the perceived involvement differs immensely among 
different groups, hierarchy levels and between phases along the innovation 
process. Hierarchy, physician-centricity and high workload limit the 
participation in innovation activities of certain groups. Further, there is a gap 
between perceived and actual involvement levels. An overview of the perceived 
involvement levels is presented in Figure 2. 
 
Figure 2 – Perceived involvement levels  
Interaction levels also differ immensely. Respondents in management positions 
report higher interaction levels compared to regular employees, who attribute 




interaction at the ideation stage and only nursing staff mentioned co-creation 
efforts with patients. The between-group interaction increases during the idea 
selection stage when it comes to more radical innovation, while incremental 
innovation, often process improvements, are mainly discussed within the 
respective group. The highest levels of interaction are perceived in the testing 
and implementation phase, particularly through involvement in clinical trials 
and training on the use of innovative technology.   
Employees with high perceived levels of involvement and interaction within 
networks appear more likely to take initiative, push and communicate projects 
and actively engage with new ideas, while staff groups with low perceived 
involvement appear reluctant to share suggestions and to communicate their 
ideas. Thus, following a hierarchy-independent open innovation approach may 
increase hospital innovation output. 
 Scientific / practical value: This research adds to the literature on innovation 
management in hospitals and employee involvement in innovation activities by 
providing a model of perceived involvement and showcasing the interaction of 
stakeholder groups in the innovation management process of a hospital. With 
this, we provide a base case for further comparative research. We discuss 
measures that allow management to foster innovative behavior in the specific 
setting of a hospital.   
 Areas of improvement: The results are based on a single qualitative case study 
and cover a limited circle of stakeholders with in-depth insights. Thus, they 
provide only a snap-shot of subjective opinions. Shadowing the employees 
would have led to a more objective assessment of their actual involvement. 
Additional qualitative research in form of a multiple case study or additional 
quantitative research based on a larger population may add to the knowledge 




4. Future research opportunities  
The field of innovation in healthcare provides a myriad of opportunities for further 
research on the macro, meso and micro level. At a macro level, it would be interesting 
to see how the innovation clusters develop in a longitudinal study and to assess which 
policy measures impact the clustering in particular. Further, a detailed case study of 
the health innovation systems of the top performing countries and the measures they 
have taken to foster innovativeness in their healthcare sector while containing cost and 
improving or maintaining patient welfare may be very insightful for policy makers and 
researchers alike. Here, it would also be interesting to analyze how the willingness to 
implement change and digitalization in the healthcare sector, as for example already 
underway in Estonia, impact the innovation output, both in the short and the long term. 
On the meso level and considering the apparent need of digitalization in the healthcare 
sector, it would be interesting to portrait cases of successful implementation of 
(digital) innovation with a large positive impact on social welfare in order to provide 
best practices for hospital management and healthcare payers. Further, it would be 
interesting to see how policy initiatives such as the “Gesetz für eine bessere 
Versorgung durch Digitalisierung und Innovation” (bill for improving care through 
digitalization and innovation), which was passed in July, 2019 by the German 
Bundestag, impact the implementation of health innovation. Likewise, given the 
importance of staff involvement in innovation for incremental process improvements 
as well as radical process changes, best practice cases and comparative case studies on 
the implementation of a (digital) hospital innovation management and the continuous 
improvement of innovation processes may be very insightful for managers. Finally, 
given the patient centricity of healthcare, involving the patient (user) in the innovation 
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Abstract: 
The importance of innovation in healthcare has increased within the last decades as 
challenges, like rising costs and an aging demographic, have to be solved. The degree 
of innovativeness in healthcare is strongly influenced by the National Health 
Innovation System, which as a sectoral innovation system encompasses a wide variety 
of actors and related knowledge. Despite the highly practical relevance of the topic, 
there are only a few studies that analyze innovation in healthcare on a national level. 
Thus, this study is a starting point and, building on the theoretical framework of 
national innovation systems, answers the following questions: “Can countries be 
grouped by their innovation output in healthcare and do those groups differ in factors 
describing the healthcare system? Do countries with strong national innovation 
systems also have strong national health innovation systems and vice versa?” We 
compare the healthcare innovation output of 30 OECD countries using a multiindicator 
approach and categorize them into four distinct groups using cluster analysis. The 
cluster consisting of the Scandinavian countries, the Netherlands and Switzerland 
shows the highest innovation output measured in knowledge production and 
knowledge commercialization. Surprisingly, these countries, with the exception of 
Switzerland, only rank in the medium group when considering the entire national 
innovation system. Policymakers and researchers might be particularly interested in 
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 Chair of Innovation Management, HHL Leipzig Graduate School of Management, Jahnallee 59,04109 Leipzig, 
Germany. julia.busch@hhl.de  
Personalised Medicine (PM) is an emerging concept which allows tailored treatments through extensive pre-
treatment diagnostics. Implementing this approach in hospitals poses a challenge. Using mass customisation 
(MC) may be a beneficial method of implementing PM in hospitals. This paper examines the feasibility and 
potential success factors for using MC as a method for implementing PM in hospitals, the status of its 
implementation of PM in Germany and potential implications for hospital management. Therefore, a 
comprehensive literature review and interviews with German practitioners were conducted. The results show that 
MC may be one way of attaining a successful PM implementation. Success factors for MC can be transferred to 
PM implementation in hospitals as there is an overlap between both concepts. However, factors such as a 
regulatory framework, ethical standards and reimbursement have to be added to the construct. Overall, PM and 
its implementation into hospital structures do not seem to be a top priority of German hospitals, speciality 
centres excluded. However, practitioners expect this to change in the upcoming years, partially due to 
Government incentive. Future research opportunities include case studies of successful PM implementation in 
different countries or quantitative surveys to allow cross-country comparisons.  
Keywords: Personalised Medicine, Mass Customisation, Healthcare, Implementation of Innovation, Germany  
1. Introduction 
The German healthcare system has undergone several changes since the millennium. Two examples are 
technological advancements in surgery techniques and the introduction of Diagnosis Related Groups (DRG) as a 
new reimbursement scheme. The latter imposed significant financial pressure on hospitals leading to increased 
efforts to improve efficiency and productivity (Korff, 2012). This pressure has been compounded by increasingly 
informed and engaged patients demanding higher levels of service and the use of the best technology available. 
“Personalised Medicine” (PM) has become a new technology through advancements in the field of genomics. It 
promises to improve the well-being of patients through the specific administration and dosage of drugs, thus 
personalising treatment and minimising potential side effects. Patients demand treatments that are adjusted to 
their individual needs, not only in terms of medicine, but also as a service experience at the hospital (Hartweg et 
al., 2014). Thus, hospitals must shape their service offerings to better compete on a regional and international 
level (Hartweg et al., 2014). Due to these developments, the Federal government of Germany has recognised PM 
as one of six action fields (BMBF, 2010). 
Other industries have successfully adopted strategies for personalising their product and service offerings. 
Such personalisation has been subject of intensive research, primarily focusing on mass customisation (MC). 
Companies can fulfil clients’ needs through integrating economies of scope with powerful IT solutions and 
forming a flexible approach in manufacturing. This paper aims to apply the concept of MC to the hospital sector, 
to assess its applicability to the implementation of PM and to identify potential success factors. Following a short 
literature overview of mass customisation and its success factors, this paper will focus on applying the recent 
literature on personalised medicine to the developed factors in order to assess the applicability of this concept. 





The research design and methodology is described in section 3. Section 4 presents the results of both literature 
analysis and interviews. The discussion of the results, their implications, and their limitations are presented in 
section 5 and conclusions in Section 6.  
2. Literature Overview 
2.1. Personalised medicine  
PM has been in the focus of medical research since the 1990s (Marshall, 1997). Both the German Federal 
Government (BMBF, 2010) and US President Barack Obama (National Institutes of Health, 2016) have 
emphasised its importance. However, PM has no widely agreed definition. Ruaño (2004) states that “medicine 
has attempted to be rather personal” (p. 1), indicating that personalising medicine is not a new topic. Swan 
(2009) suggests “A systemic approach may incorporate a combination of an individual’s genetic, blood and other 
biomarker, environmental, lifestyle and other data” (p. 503) as a comprehensive definition. Schleidgen et al. 
(2013, p.14) state that PM “seeks to improve stratification and timing of healthcare by utilizing biological 
information and biomarkers on the level of molecular disease pathways, genetics, proteomics as well as 
metabolomics”. For this paper, the broader definition of Swan (2009) is applied.  
The notion that PM may lead to better health has mainly been analysed from a biological standpoint. It is 
mostly based on biomarkers and clinical studies (among others Ross et al., 2009). Additional research was 
conducted from a pharmaceutical perspective (Amir-Aslani & Mangematin, 2010, Haruya & Kano, 2015). 
Despite the clear value proposition of more targeted treatments and the reduction of potential side effects and 
ineffective treatments (among others Collins & Varmus, 2015), the implementation of PM in hospitals has been 
characterised as sporadic and slow (Simmons et al., 2012, Teng, 2015). This may be due to a lack of evidence as 
studies on efficacy, safety, clinical utility, and cost-effectiveness progress slowly for smaller, harder to assemble 
patient cohorts (Sorich & McKinnon, 2012, Frueh , 2013, Manolio et al., 2015). Ways to foster implementation 
have only been the subject of a few studies (e.g. PWC, 2011, Fenstermacher et al., 2011). Current research is 
mainly based on case studies of hospitals and comprehensive cancer centres. It describes the implementation of 
the relevant IT-systems and changes in their internal processes as well as their status of implementation (PWC, 
2011, Roden et al., 2008, Manolio et al. 2015, Bonter et al., 2011, Kron et al., 2016). However, current research 
lacks widely applicable implications for hospital managers in other sectors and other regulatory environments. 
2.2. Mass customisation  
Research on mass customisation (MC) mainly discusses the demand-side dynamics of more fragmented 
markets and increasingly educated customers (Gilmore & Pine, 2000). The goal of MC is to provide superior 
customer value by generating goods and services that meet individual customer needs with a close to mass 
production efficiency (Tseng and Jiao, 2001). The benefits of MC for companies include:  
 
 Better match to the customer needs (Gilmore & Pine, 1997) 
 Increased interaction with customers through co-creation and better customer understanding (Prahalad 
& Ramaswamy, 2004, Piller, 2004) 
 Increased willingness to pay by the customer (Cavusoglu et al., 2007) 
 Improved customer loyalty (Piller, 2004) 
 Differentiation from competition (Broekhuizen & Alsem, 2002) 
 
MC strategies (Lampel & Mintzberg, 1996, Kumar, 2004) are aided by the advances in manufacturing and 
information technology as well as just-in-time processes (Cavusoglu et al., 2007). It has been implemented, for 
example, in the bike, apparel or electronics industry (Kumar, 2004, Hvam, 2006). However, especially in 
established markets, the customisation of any product may be challenging and costly for the manufacturer 
(Cavusoglu et al., 2007). It may also be confusing and overwhelming for the consumer (Miceli et al., 2007). 
Thus, Cavusoglu et al. (2007) propose “targeted mass customisation” as a hybrid strategy. A company offers 
multiple customization scopes, that each represent a range of customised products instead of continuous 
customised varieties. With this approach, there is also the option of customising targeted segments. This leaves 
other segments to be served by a standard product variety. In this context, Cavusoglu et al. (2007) conclude that 





have to carefully consider whether to customise at all. If they do, they have to assess which company segment 
will profit most from an added USP at the lowest possible cost of technology and most profit from gathering 
customer insights. Success factors of MC have been the focus of research papers for some time (Hart, 1994, 
Broekhuizen & Alsem, 2002, Piller, 2004). Among those, Broekhuizen & Alsem (2002) have proposed a model 
of success factors that influence a fruitful adoption of mass customisation by an organisation. External factors 
include: customer factors, product factors, market factors, industry factors. Internal factors are classified as 
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Figure 1 – Success factors for MC, adapted from Broekhhuizen & Alsem, 2002 
 
This model shows an approach for assessing whether MC is useful and practical for a business, as it not only 
encompasses market factors but also evaluates the internal capabilities of a company. The defined success 
factors have been confirmed in further studies (Merle et al., 2007). 
2.3. Mass customisation for personalised medicine  
The literature on MC in healthcare is rather limited. Healthcare as a service is by nature tailored to the 
symptoms of a specific patient. Lampel & Mintzberg (1996) proposed a tailored customisation, presenting the 
customer with a standard which is then adapted to customer needs. Current research is looking at a systemic 
solution, thus tailoring the patient pathway across all respective providers (White & Chao, 2014). While this 
value-based, patient-centred approach should ultimately be the goal of an efficient healthcare system (Porter, 
2006); it seems far from being realised in practice (Porter, 2009). Thus, enabling hospitals as major drivers in the 
healthcare system to successfully adopt PM appears to be a step towards a more patient-centred, value-based 
healthcare. Chaudhuri & Lillrank (2013) provide a first insight into customisation in healthcare and the trade-off 
between resources and flow efficiency in the Indian healthcare sector. The authors identify several research gaps 
including competencies and advances needed for MC implementation and the dimensions of the competitive 
advantages for hospitals and how both factors can be combined. Minvielle et al. (2014) have suggested a first 





sector literature. They develop six relevant factors for implementing care customisation: categorisation, IT use, 
developing service skills, patient self-management, patient’s experiences and economic impact. They also 
introduce the term “care customisation”, meaning the “uniqueness of each care process” (Minvielle et al., 2014) 
in contrast to patient-centred care referring to large-scale actions such as IT implementation and comprehensive 
care standards. The model is of theoretical nature and has not yet been supported by data. Pourabdollahian & 
Copani (2015) propose four different business models for customisation in healthcare based on a product service 
system and evaluate them based upon a qualitative analysis of benefits and challenges. Their approach is 
theoretical and does not provide the reader with case studies or data on the implementation of such business 
models. Thus, research is currently based on theoretical concepts, which have not yet been evaluated by 
practitioners. The majority of studies focuses on the US market, with research on other health-regulatory 
environments being rather underrepresented in the reviewed literature (Manolio et al. 2015 provide 
comprehensive insights into global developments in PM). Currently, there seems to be no research that provides 
data for insights into the possible implementation of MC in healthcare in general or in a country-specific setting. 
Those factors pose relevant research gaps, which will be addressed in this paper.  
3. Research design 
The increased scientific interest in PM and its translation into clinical practice pose a very interesting 
research opportunity. In accordance with Minvielle et al. (2014) this paper postulates that MC may be beneficial 
for implementing PM in the hospital sector. Since there is only limited research on country-specific 
implementation, this paper aims to provide insights from a German perspective. Therefore, the objective of this 
research project is to investigate the following questions:  
 
1. Is it beneficial to apply the concept of MC to hospitals in the context of PM? 
2. What are potential success factors?  
3. What is the status of PM implementation in Germany?  
4. What are the implications for PM in German hospitals? 
 
The MC framework of Broekhuizen & Alsem (2002, cf. Figure 1) is applied to PM through a comprehensive 
literature review in order to answer questions one and two. Each factor of the framework is analysed for its fit to 
PM to determine whether the model is beneficial in the application context.  
First, a Google Scholar search for “personalised medicine” in conjunction with “concept” was conducted to get 
an initial overview of the relevant literature. For this purpose, the first 20 result pages were screened which 
resulted in 31 relevant research articles. Further, an EBSCO search using the terms “personalised medicine” in 
combination with “concept” was conducted. The literature was then screened for papers focusing on the PM 
concept.  
In a next step, citations of the chosen papers were scanned for further relevant research. Overall, 70 studies were 
reviewed for the literature analysis section. The selected papers were published between 1999 and 2016. Of 
these, 71% have been published since 2009. Statements matching the categories defined according to 
Broekhuizen & Alsem (2002) and some additional factors were compiled in a database.  
For questions three and four, ten semi-structured interviews with German practitioners were conducted. Their 
aim was to get an overview of the status of PM across Germany as well as of the practicability and applicability 
of the model. The sampling of the participants was done conveniently. The interview goal was to get responses 
from relevant stakeholders: physicians (1 participant), hospital management (3), special PM centres (1), the 
medical technology industry (1), pharmaceutical industry (1), medical IT industry (1), health insurance sector (1) 
and academia (1). Overall, all interviews were conducted between January and April 2016. Each interview lasted 
between 25 and 45 minutes. The survey questions were derived based upon the model of Broekhuizen & Alsem 
(2002). The questions were clustered into four parts: (A) general questions, (B) the concept of PM, (C) 
implementation of PM and (D) future of PM in Germany. Both (A) and (B) focused on external factors defined 
in the model. Part (C) concentrated on respective internal factors. The questions were slightly adapted to the 
professional background of the interview participants. For convenience purposes of the partners, the interviews 







4. Results  
4.1. Literature analysis 
The results gathered from the literature review indicate that the success factors for mass customisation can be 
applied to personalised medicine. Figure 2 shows an overview of how many papers presented statements that 
match the categories of the model by Broekhuizen & Alsem (2002). 
  
External influence factors include: (i) customer factors, (ii) product factors, (iii) market factors, and (iv) 
industry factors. Customer factors comprise of customer heterogeneity, customer involvement, willingness to 
pay price premium, and privacy concerns (having a negative impact on the success of MC). Reviewing the 
papers indicated that customer heterogeneity is widely accepted, with papers stating “Humans are individual, so 
medicine must be” (Fierz, 2004, p. 119) or “Recognition of interindividual differences in drug response is an 
essential step towards optimizing therapy” (Mancinelli et al., 2000, p.1). Statements relating to customer 
involvement were found in approx. 40% of the reviewed papers. Evidence for an increased willingness to pay 
additional costs could be revealed in several papers. However, some of the articles state that there may not be an 
increased willingness to pay (by the health insurances) due to a persisting lack of clinical evidence (Ginsburg & 
Willard, 2009, Horgan et al., 2014). Further, some suggest that PM may lead to an overall cost reduction through 
e.g. disease prevention (Aspinall & Hamermersh, 2007). The negative impact of privacy concerns of data 
security was found in 30% of the papers. Relating to the data security, fears of discrimination due to leaked 
genomic information were raised (Savard, 2013, Swan, 2009, Yang et al., 2011). 
Product factors include purchasing frequency, visibility, luxury, and adaptability, the latter referring to the 
ease of adapting the product to target more segments. Interestingly, there were no statements found to match the 
category purchasing frequency. This indicates that returning patients (e.g. chronically ill) are not relevant for the 
implementation of MC in healthcare. Statements referring to the visibility in a sense of using health as a factor of 
self-expression (Swan, 2009) could be found in a few papers. Luxury was only rarely mentioned. Adaptability 
was mentioned more frequently mostly referring to adaptability of treatment to heterogeneous customers 
Figure 2 – Results of literature analysis for personalised medicine (model adapted from Broekhuizen & Alsem, 2002) 
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(Mancinelli et al., 2000).  
Market variety and retailer’s willingness and ability are combined to form market factors. Several papers 
mention market variety – mostly concerning available biomarkers and genomic tests (Conti et al., 2010, 
Hamburg & Collins, 2010). Some also mention the different stages of PM implementations (Horgan et al., 
2014). The retailers’ ability and willingness is evaluated differently, since PM is a service that is aided by several 
products. Rather, PM is consumed at the time of creation (Hartweg & Lindgren, 1993) or possibly with a slight 
delay due to lab results. There is no need for a retailer from a hospital point of view. Thus, the retailer’s 
willingness is interpreted here as the “healthcare providers’ willingness and ability” from a market perspective. 
This ability was mentioned frequently in the literature. However, it was mostly referring to reluctant adaptation 
of the concept. For example, Davis (2009) states that only “few personalised medicine tests have been widely 
adopted in the clinic so far” (p. 279). Horgan et al. (2014) postulate “The complex process to translate PM into 
the member states and European health systems has delayed its uptake.” (p. 278) Several papers identify 
institutional and systemic barriers to a widespread adoption of PM, which include, among others, knowledge, 
regulation, education, or ethical concern (Lundshof et al. 2006, Horgan et al., 2014). 
Industry factors comprise of IT growth, E-commerce growth, and production technology growth. IT-growth 
is widely mentioned, specifically referring to the possibilities of Electronic Health Records (Bonter et al., 2011), 
Big Data (Harvey et al., 2012, Swan, 2012), Quantified-Self (Swan, 2012), shared data (Luciano et al., 2011, 
PWC, 2011), and predictive algorithms (Kohane, 2009, Swan, 2009). E-commerce is rarely mentioned, only 
referring to direct-to-customer genetic testing as pioneered by companies such as 23 and me (Swan, 2012). 
Approximately 45% of the analysed literature refers to production technology growth in genomic research, 
biomarkers, and related second generation sequencing technologies. However, Harvey et al. (2012) state that 
“new technologies for detailed biological profiling of individuals at the molecular level have been crucial in 
initiating the move to personalised medicine; further novel technologies will be necessary if the vision is to 
become a reality.” (p. 625). It is another indicator for the slow implementation of PM. Challenges such as 
standards to ensure interoperability and harmonisation of different therapies pertain (Ginsburg & McCathy, 
2001, Horgan et al., 2014).  
Internal factors include company capabilities and movers towards MC. Company capabilities comprise of 
manufacturing flexibility, distribution and logistics flexibility, information and knowledge system as well as 
first-mover advantage. Manufacturing flexibility is interpreted as “service flexibility” since PM as a service is 
consumed at the time of creation (Bowen, 1990). A few papers refer to the service-delivering process. Bonter et 
al. (2011) state that “Canadian and US studies have demonstrated that current physician knowledge, real-world 
data and guidelines relating to PM have often been insufficient for appropriate adoption […]” (p. 6). A need for 
education of current and future service providers was mentioned frequently (Cornetta & Brown, 2014, Hall et al, 
2015, Keller, 2010). However, distribution and logistics flexibility was only rarely mentioned. Relating papers 
only suggested integrating PM processes (testing, genetic counselling, etc.) into comprehensive patient care 
(Fierz, 2004, Merci-Bernstam et al., 2013). The information and knowledge system was frequently mentioned. 
Most of the statements in this field referred to the need for solutions that deal with the generated data and related 
issues such as storage, interoperability of systems, computer-assisted decision-making etc. (Horgan et al, 2014, 
Swan, 2009 and 2012, Stelzer et al., 2015). Interestingly, there were almost no statements referring to a first 
mover advantage. Movers to MC include available resources and readiness to change. Statements about 
resources mostly referred to the lack thereof (Yang et al., 2011, PWC, 2011, Meric-Bernstam et al., 2013). 
Readiness to change, or more precisely, the lack thereof, was also mentioned in several papers. PM “may not be 
seen as a priority” (Swan, 2012, p.112) or there may be “a timing issue” (Swan, 2012, p. 112), as the 
technologies still undergo extensive R&D and may not be in the full focus of healthcare providers yet.  
Finally, the success factors seen from the customer’s perspective are divided into customer perceived costs 
and customer perceived benefits. Customer perceived costs include price premium, additional time and effort 
required and increased uncertainty. There are two polarized opinions regarding the price premium: overall cost 
reduction (Faulkner et al., 2012, Flores et al, 2013) and overall cost increase (Sorich & McKinnon, 2012). Teng 
(2015) states that PM “is not usually synonymous with low costs” (p. 232). He adds, however, that it will lead to 
more elaborate prevention and care, thus reducing overall healthcare costs through early detection and treatment. 
The need for adequate reimbursement is yet another frequently mentioned factor (Davis, 2009, Ginsburg & 
Willard, 2009, Hitz & Katsanis, 2014). Additional time and effort required is rarely mentioned. Statements refer 
to an increased effort for longitudinal data collection (Chang & Ginsburg, 2011) for healthcare providers. 
However, increased effort is also mentioned for patients as they seek to be active about their health, their relating 
data and its potential implications (Gonzales-Angulo et al., 2010). Increased uncertainty is mentioned very 





in: physicians’ and patients’ uncertainty about “the right treatment” (Chan & Ginsburg, 2011, Cornetta & 
Brown, 2014, Horgan et al., 2014), patients’ uncertainty about data collection, storage, privacy, and handling 
(Burke et al., 2010), payers’, physicians’ and patients’ uncertainty about efficacy of methods (Conti et al., 2010, 
Hamburg & Collins, 2010, Hitz & Katsanis, 2014), and healthcare providers’ and industries’ uncertainties about 
reimbursement (Faulkner et al, 2012). Consumer perceived benefits consist of instrumental benefits (better 
quality products and services) and hedonistic benefits (more enjoyable “shopping experience”). The latter is 
translated into a “more enjoyable healthcare experience” for the purpose of this paper. Better quality, mostly 
defined as higher efficiency and efficacy of treatment, is explicitly mentioned in almost 40% of the analysed 
articles. This factor is viewed as the main goal of PM (Horgan et al., 2014). Hedonistic benefits were only rarely 
mentioned. As PM involves undergoing intensive tests, patients may not experience hedonistic benefits in the 
service co-creation.  
In addition to the factors found by Broekhuizen & Alsem (2002), several others were identified for a 
successful implementation of PM in hospitals:  
1. Definition and uphold of guiding ethical principles as well as “the right not to know” (Burke et al, 2010, 
Cornetta & Brown, 2014, Hall et al., 2014) 
2. Effective regulatory policies and set standards for PM (Chan & Ginsburg, 2011, Davis, 2009) 
3. Clear reimbursement standards (Faulkner et al., 2012) 
4. Education of all stakeholder groups on the meaning of PM (Keller, 2010, PWC, 2011). 
4.2. Interviews 
The interviews confirmed that there is no clear, overarching understanding and definition of PM. Every 
interviewee had a different understanding when asked for a definition. One partner had not previously come 
across the term at all, despite working with hospitals. Statements like “PM is observing and acting on the current 
needs and concerns of the patient in an individualised fashion” or “using the technical possibilities and processes 
of teams for individualising standard-based [treatments]” occurred. Standardised processes were frequently 
mentioned as a basic need for PM. Some participants mentioned that personalisation may not be feasible for 
single patients, but rather for cohorts or sub-cohorts. The lack of common understanding may result in a delayed 
adoption. 
 The results of the interviews further indicate that the model of MC success factors is applicable to the 
German healthcare sector; however, minor adaptions have to be made. External factors of the framework were 
mentioned by all partners during the interviews. All customer factors were frequently referred to. Customer 
involvement was almost always linked with statements like “customers are increasingly informed”, partially due 
to available information in online resources. Customers and their demand were perceived as heterogeneous. 
Interviewees proposed a distinction of customer demands depending on the severity of their illness. Participants 
from non-specialised centres did not experience patient demand yet. Specialised centres, however, reported an 
increase. There was no consensus whether patients are willing to pay for PM services. However, the challenges 
of adequate reimbursement were frequently mentioned. All interview partners stated concerns about privacy and 
data protection, even though some agreed that some patients are already sharing their data for research purposes. 
As in the literature review, product factors were rarely mentioned by the interviewees. Only adaptability of the 
service occurred, often with the notion that standardisation of processes enables individualisation. This seems to 
be an important point for German stakeholders. Market factors were rarely stated in the interviews. Variety was 
not stated, possibly due to the lack of awareness of PM projects among the interviewees. Most said that they are 
not able to state beacon projects of PM in Germany. Only the partners most closely linked to PM research and 
reimbursement revealed two to three current German initiatives. All of those are carried out by specialised 
university hospitals. Interestingly, the company 23 and me was mentioned several times in the context of beacon 
projects. Statements about healthcare providers’ willingness and ability lead to differing viewpoints: when 
considering the payers, most stated reimbursement issues that prolong implementation. Considering the 
hospitals, almost all interviewees highlight that PM “will come and must come” to the German market. 
However, adoption may only be useful and feasible for specialised centres or university clinics. Industry factors, 
meaning IT growth and production technology growth, were stated very frequently. There were no statements 
concerning E-Commerce, which is in line with the literature analysis. Finally, regulatory issues were derived as a 
further success factor, which is in accordance with the literature analysis. Participants stated that there may be 
too much regulation, which may hinder the implementation of PM in German hospitals. It was suggested that a 
clear regulatory framework for reimbursement is required. Almost all participants raised ethical concerns about 





Internal factors were also frequently mentioned. Participants highlighted the need for employee involvement 
and initiative as a main factor for implementing PM service capabilities in a hospital. It may be aided through 
internal systems, specific rewards and internal education as enablers. The statements are consistent with the 
literature review results. Interviewees rarely mentioned distribution and logistics flexibility, however, they 
emphasised the need for new organisational standards, breaking up existing hierarchies, and team work. This 
relates to all hospital staff and cooperation with stakeholders. All partners identified IT-systems as one of the 
most relevant factors for PM and changes in healthcare in general. However, the status in Germany was assessed 
with statements such as “not enough IT, not enough hardware, outdated hardware”, “IT departments can barely 
handle the amount of data generated” but also “we had to cancel [the implementation of Electronic Health 
Records] due to financial reasons”. They indicate that outdated, not interoperable IT systems and a lack of 
resources to replace them pose a strong barrier for PM implementation. Further, (anonymised) data sharing was 
perceived as impossible by many partners due to very strict German data security regulations. A first-mover 
advantage was stated by a few participants. Resources and readiness to change were pointed out by almost all 
participants as movers (or the lack thereof as barriers) for PM. Available resources were referred to as being 
critical to success. Sources of additional financial resources may be obtained through external grants, which may 
also serve as a motivating factor for staff. Readiness to change was perceived as a “management issue” by the 
participants. Successful implementation is accompanied by a strategic decision towards PM.  
Better quality of service was mentioned as the most important goal of PM and thus a major success factor. 
However, better service was often attributed to non-medical service experiences such as better rooms, reduced 
waiting times or friendly staff as a way to “personalise” medicine. This adds more to the hedonistic “more 
enjoyable service experience”. With regard to better quality, risk prediction and non-genomic, preventive 
measures were also stated. Some subjects attributed this to be a responsibility of payers. All agreed that a high 
level of uncertainty pertains – about the definition of PM, the efficacy of new treatments, data security, 
potentially predictive qualities of tests, efficacy and “false positives”. Additional time and effort for the patient 
was stated by several partners. However, there was consensus that patients incur this additional time already in 
order to gather information about their illness. Finally, the overall notion was that PM comes at a price premium. 
There was no agreement on whether PM will reduce the overall healthcare cost.  
 
5. Discussion and Implications 
The results of the literature analysis and the interviews indicate that MC may be beneficial for hospital 
implementation of PM. However, adaptions may be required. In both, the literature and the interviews, no clear 
definition of the concept of personalised medicine could be revealed. Therefore, a diverse understanding of the 
term and concept resulted among the stakeholders. Thus, PM is often used as a “buzz word” with no clear 
understanding of its implications. A common understanding between the stakeholders needs to be established to 
enable a fruitful discussion of the topic.  
Additionally, there is a difference in perceived value of PM between the stakeholders. A core concept of 
German healthcare is the divide between the healthcare receiver (patient) and healthcare payer (health 
insurance). The results indicate that there is uncertainty about whether PM does lead to better healthcare 
economics for the overall healthcare system. Cost of customised testing, care plans and treatment may be higher 
in the short term. However, PM may also lead to reduced overall lifetime treatment costs for the patient. On the 
other hand, personalising every treatment may result in a cost explosion. Performing quantitative research on this 
question would be beneficial for all stakeholders, as it enables a more economic view on the subject. 
There also seem to be specific “German phenomena” regarding the implementation of PM. Very strict rules 
on data security and data sharing make sharing data within overarching biobanks or similar IT systems nearly 
impossible. Further, current IT in German hospitals seems entirely unfit for the challenges of genomics data 
creation, usage and storage. This may partly be due to a lack of hospital IT infrastructure funding in relation to 
the DRG introduction. Additionally, the German population is very concerned about gene manipulation. This 
may explain comparatively low patient demand and a related delayed adoption of genomics based medicine, 
even within larger clinics. The current view is that PM is only a topic for a relatively small number of diseases, 
mostly cancer, and thus only a relevant concept for university hospitals and specialty clinics in Germany. 





research specifically aimed at PM basic and translational research (BMBF, 2016). Additionally, there will be 
changes in reimbursement, such as the introduction of reimbursement for specific companion diagnostic tests 
(KBV, 2016). This may set incentives for a broader adoption of PM.  
The model of success factors for MC seems to be a good starting point for implementing PM. This is due to a 
significant overlap of external, internal and final success factors. However, some factors were not seen as 
important, while new ones were emphasised in the results. Factors such as purchasing frequency (e.g. referring 
to chronic patients) or E-Commerce growth were not seen as important for PM, and hence removed from the 
model. The literature review and interviews revealed several other factors that are of relevance for PM 
implementation. These include a clear reimbursement framework, education of relevant stakeholders, ethical 
standards and clear regulations seem to play an important role for PM. Reimbursement of e.g. companion 
diagnostics incentives the use of the new technologies. Further stakeholder education appears necessary to 
increase awareness and increase understanding of the possibilities, challenges and implications of PM. Ethical 
standards and regulatory clarity provide security for hospitals wanting to implement PM. Thus, those factors 
were added to the framework. Moreover, two additional movers towards PM were identified in the literature 
review and interviews: employee initiative and management readiness to change. Hedonistic benefits were left 
within the model, as German partners were heavily focused on the overall hospital service experience. The 
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Figure 3 – New model of factors for successful PM implementation, 
 
There are numerous implications for German hospital practitioners. First, there is a pressing need to find a 
common understanding of the concept of PM in order to facilitate a political, regulatory and financial discussion 
about the topic. A first starting point for the discussion may be the “Aktionsplan Individualisierte Medizin” by 
the Federal Ministry for Research & Education (BMBF, 2016), which offers research grants for basic research, 
but also for translation into clinical practice. Additionally, PM should not only be recognised as a better service 
for patients, but rather as a customised treatment plan for a (sub-) cohort of patients. Further, practitioners should 
familiarise themselves with the concept, the successes and failures of mass customisation and draw lessons on 
the implications of MC for PM and possible limitations of the concept. Hospital key performance indicators 
should be set, measured and analysed accordingly. Interesting input may arise from other countries, such as the 
United States or Asian countries. Finally, German hospital practitioners will have to accept a slowly increasing 





to the “-omics” subjects. Thus, if a hospital wants to be prepared for the future, there is a need to find ways to 
finance and use new technologies in order to stay ahead in the market place. A strategic focus on PM may help 
in this regard. The derived success factors may provide first guidance in developing a PM strategy.  
This paper has several limitations and shows opportunities for further research. First, although the literature 
review can be regarded as comprehensive, research results may have been neglected due to the vast amount of 
PM literature. Further, the model is derived based on one specific framework of MC success factors. There may 
be other models, which may be adapted to healthcare. In addition, the framework wording was modified to fit the 
healthcare industry. Thus, a more in-depth bibliometric analysis of the derived model may pose an interesting 
research opportunity. Second, the interview sampling was done conveniently and presents only a small fraction 
of the relevant stakeholders. It can thus only represent a contemporary snapshot of stakeholder opinions. 
Additionally, the stakeholder sample is, despite the author’s efforts, not fully comprehensive, as it does not 
include general practitioners, patients or representatives from the Federal Government. Thus, for further 
research, the sample should be extended to all relevant stakeholders. As with qualitative research, the results of 
this paper cannot be generalised. Thus, additional quantitative research, e.g. an empirical study of the different 
stakeholder groups, may add to the knowledge base and provide relevant insights. Additionally, the derived 
model of PM success factors has not been tested in a quantitative study, which may be an interesting future 
research opportunity. Other research opportunities may include applying the proposed framework to a “real-life” 
case study of PM implementation, both in Germany and other countries. Additionally, a cross-country case-
comparison may lead to more comprehensive policy implications.  
6. Conclusion 
This paper aimed at analysing the applicability of the concept of MC to PM in a German context. Additionally, 
the status of PM implementation in Germany was assessed. In order to evaluate the adaptability of MC to the 
specifics of PM in Germany, a comprehensive literature review was carried out. Further, semi-structured 
interviews with experts from the German medical sector were conducted. The results show that MC may be one 
way through which implementing PM is possible. The success factors for MC can be transferred to PM with 
minor adaptions of the model. Overall, however, PM seems to not be in the focus of German hospitals at the 
moment. As the technological and medical advancements progress and additional funding is provided by the 
Federal Government, focus will shift towards this evolving concept. However, it is necessary to first establish a 
common definition of the concept. Afterwards, there will be a need for developing implementation strategies and 
defining success factors. The results of this paper may be a starting point for further, in-depth research of PM in 
the German healthcare sector.  
References  
 
Amir-Aslani, A., and V. Mangematin. 2010. “The future of drug discovery and development: shifting emphasis 
towards personalized medicine.” Technological Forecasting and Social Change 77(2): 203–217. 
Aspinall, M. G., and R. G. Hamermesh. 2007. "Realizing the promise of personalized medicine." Harvard 
Business Review 85 (10): 108. 
BMBF. 2010. Rahmenprogramm Gesundheitsforschung der Bundesregierung”. [derived on March, 15
th 
2016 
from https://www.bmbf.de/pub/Rahmenprogramm_Gesundheitsforschung.pdf].  
BMBF. 2016. “Aktionsplan Individualisierte Medizin” [derived on April, 15
th
 2016 from 
https://www.bmbf.de/pub/BMBF_Aktionsplan_IndiMed.pdf]. 
Bonter, K., et al. 2011. "Personalised medicine in Canada: a survey of adoption and practice in oncology, 
cardiology and family medicine." BMJ open 1 (1): e000110. 
Bowen, J. 1990. “Develop of a taxonomy of services to gain strategic marketing insights.” Journal of the 
Academy of Marketing Science 18 (1): 43-49. 
Broekhuizen, T. L. J., and K. J. Alsem. 2002. “Success factors for mass customization: a conceptual model.” 





Burke, W., et al. 2010. "Extending the reach of public health genomics: what should be the agenda for public 
health in an era of genome-based and “personalized” medicine?" Genetics in Medicine 12 (12): 785-791. 
Cavusoglu, H., H. Cavusoglu, and S. Raghunathan. 2007. “Selecting a customization strategy under competition: 
Mass customization, targeted mass customization, and product proliferation.” IEEE Transactions on Engineering 
Management 54 (1): 12-28. 
Chan, I. S., and G. S. Ginsburg. 2011. "Personalized medicine: progress and promise." Annual Review of 
Genomics and Human Genetics 12: 217-244. 
Chaudhuri, A., and P. Lillrank. 2013. “Mass personalization in healthcare: insights and future research 
directions.” Journal of Advances in Management Research 10 (2): 176-191.  
Collins, F.S., and H. Varmus. 2015. “A new initiative on precision medicine.” The New England Journal of 
Medicine 372 (9): 793-795. 
Cornetta, K., and C. G. Brown. 2013. "Perspective: balancing personalized medicine and personalized care." 
Academic Medicine: Journal of the Association of American Medical Colleges 88 (3): 309. 
Conti, R., et al. 2010. "Personalized medicine and genomics: challenges and opportunities in assessing 
effectiveness, cost-effectiveness, and future research priorities." Medical Decision Making 30 (3): 328-340. 
Davis, J. C., et al. 2009. "The microeconomics of personalized medicine: today's challenge and tomorrow's 
promise." Nature Reviews Drug Discovery 8 (4): 279-286. 
Downing, G. J., et al. 2009. "Information management to enable personalized medicine: stakeholder roles in 
building clinical decision support." BMC Medical Informatics and Decision Making 9(44). 
Faulkner, E., et al. 2012. "Challenges in the development and reimbursement of personalized medicine—payer 
and manufacturer perspectives and implications for health economics and outcomes research: a report of the 
ISPOR Personalized Medicine Special Interest Group." Value in Health 15 (8): 1162-1171. 
Fenstermacher, D. A., et al. 2011. "Implementing personalized medicine in a cancer center." Cancer Journal 
(Sudbury, Mass.) 17 (6): 528-536. 
Fierz, W.. 2004. "Challenge of personalized health care: to what extent is medicine already individualized and 
what are the future trends?" Medical Science Monitor 10 (5): RA111-RA123. 
Flores, M., et al. 2013. "P4 medicine: how systems medicine will transform the healthcare sector and society." 
Personalized Medicine 10 (6): 565-576. 
Frueh, F. W. 2013. "Regulation, reimbursement, and the long road of implementation of personalized 
medicine—a perspective from the United States." Value in Health 16 (6): S27-S31. 
Gilmore, J.H., and B. J. II Pine. 1997. “ The four faces of mass customization.” Harvard Business Review 75: 
91-101. 
Gilmore, J. H., and B. J. II Pine. 2000. Markets of One: Creating Customer-Unique Value Through Mass 
Customization. Boston: Harvard Business School Press. 
Ginsburg, G. S., and H. F. Willard. 2009. "Genomic and personalized medicine: foundations and applications." 
Translational Research 154 (6): 277-287. 
Ginsburg, G. S., and J. J. McCarthy. 2001. "Personalized medicine: revolutionizing drug discovery and patient 
care." Trends in Biotechnology 19 (12): 491-496. 
Gonzalez-Angulo, A. M., B. TJ Hennessy, and G. B. Mills. 2010. "Future of personalized medicine in oncology: 
a systems biology approach." Journal of Clinical Oncology 28 (16): 2777-2783. 
Hall, M. J., et al. 2015. "Understanding patient and provider perceptions and expectations of genomic medicine." 
Journal of Surgical Oncology 111 (1): 9-17. 
Hamburg, M. A., and F. S. Collins. 2010. "The path to personalized medicine." The New England Journal of 
Medicine 363 (4): 301-304. 
Hart, C. W. L. 1994. “Mass customization: conceptual underpinnings, opportunities and limits.“ International 





Hartweg, D. E., and J.H. Lindgren. 1993. “Consumer evaluations of goods and services: implications for 
services marketing.” Journal of Services Marketing. 7 (2): 4 – 15. 
Hartweg, H. R., R. Kaestner, H. Lohmann, M. Proff, and M. Wessels. 2014. Verbesserung der Performance 
durch Open Innovation-Ansätze: Von neuartigen Verfahren zur Suche nach Differenzierungsvorteilen im 
Krankenhaus. Wiesbaden: Springer. 
Haruya, M., and S. Kano. 2015. “A new look at the corporate capability of personalized medicine development 
in the pharmaceutical industry.” R&D Management 45(1): 94–103. 
Harvey, A., et al. 2012. "The future of technologies for personalised medicine." New Biotechnology 29 (6): 625-
633. 
Hitz, A., and L. Prevel Katsanis. 2014. "A consumer adoption model for personalized medicine: an exploratory 
study." International Journal of Pharmaceutical and Healthcare Marketing 8 (4): 371-391. 
Horgan, D., et al. 2014. "An index of barriers for the implementation of personalised medicine and 
pharmacogenomics in Europe." Public Health Genomics 17 (5-6): 287-298. 
Hvam, L. 2006. “Mass customisation in the electronics industry: based on modular products and product 
configuration” International Journal of Mass Customization 1 (4): 410-426. 
KBV. 2016. “Weiterentwicklung der humangenetischen Gebührenordnungspositionen zum 1. Juli.” [Derived on 
March 31
st
, 2016 from http://www.kbv.de/html/1150_21752.php] 
Keller, M., et al. 2010. "Coriell Personalized Medicine Collaborative: a prospective study of the utility of 
personalized medicine." Personalized Medicine 7 (3):301-317. 
Kohane, I. S. 2009. "The twin questions of personalized medicine: who are you and whom do you most 
resemble." Genome Medicine 1 (1): 4. 
Korff, U. 2012. Patient Krankenhaus. Wie Kliniken der Spagat zwischen Ökonomie und medizinischer 
Spitzenleistung gelingt. Wiesbaden: Springer. 
Kron, F. et al. 2016. "Cancer care: new value chains challenge German hospital structures – A comprehensive 
cancer perspective." In Albach, H., Meffert, H., Pinkwart, A., Reichwald, R., and von Eiff, W. (Eds.) 2016. 
Boundaryless Hospital. Rethink and Redefine Health Care Management. Berlin Heidelberg, Springer 
Kumar, A. 2004. “Mass customization: metrics and modularity.” The International Journal of Flexible 
Manufacturing Systems 16: 287-311. 
Lampel, J., and H. Mintzberg. 1996. “Customizing customization”. Sloan Management Review 38 (1): 21-30. 
Luciano, J. S., et al. 2011. "The translational medicine ontology and knowledge base: driving personalized 
medicine by bridging the gap between bench and bedside." Journal of Biomedical Semantics 2 (2): S1. 
Lunshof, J. E., M. Pirmohamed, and D. Gurwitz. 2006. "Personalized medicine: decades away?” 
Pharmagenomics 7 (2): 237-241. 
Mancinelli, L., M. Cronin, and W. Sadée. 2000. "Pharmacogenomics: the promise of personalized medicine." 
AAPS PharmSciTech 2 (1): 29-41. 
Manolio, T. A., et al. 2015. "Global implementation of genomic medicine: We are not alone." Science 
Translational Medicine 7 (290): 290ps13-290ps13. 
Marshall, A. 1997. “Laying the foundations for personalized medicines.” Nature Biotechnology 15: 954–957. 
Meric-Bernstam, F., et al. 2013. "Building a personalized medicine infrastructure at a major cancer center." 
Journal of Clinical Oncology 31 (15): 1849-1857. 
Merle, A., J.-L. Chandon, and F. Alizon. 2007. “Perceived value of the mass-customized product and mass 
customization experience for individual consumers.” Production and Operations Management 19 (5): 503-514. 
Miceli, G., F. Ricotta, and M. Costabile. 2007. “Customizing customization: A conceptual framework for 
interactive personalization.” Journal of Interactive Marketing 21 (2): 6-25. 
Minvielle, E., et al. 2014. "Managing customization in health care: A framework derived from the services sector 





National Institutes of Health. 2016. Precision medicine initiative cohort program. [derived on 28.01.2016 from 
https://www.nih.gov/precision-medicine-initiative-cohort-program]  
Piller, F.T. 2004. “Mass customization: reflections on the state of the concept.” The International Journal of 
Flexible Manufacturing Systems 16: 313-334. 
Porter, M. E., and E. O. Teisberg. 2006. Redefining health care: creating value-based competition on results. 
Boston: Harvard Business Press. 
Porter, M. E. 2009. “A strategy for health care reform—toward a value-based system.” The New England 
Journal of Medicine 361(2): 109-112. 
Pourabdollahian, G., and G. Copani. 2015. “Proposal of an innovative business model for customized production 
in healthcare.” Modern Economy. 5: 1147-1160. 
Prahalad, C.K., and V. Ramaswamy. 2004. “Co-creation experiences: the next practice in value creation.” 
Journal of Interactive Marketing 18 (3): 6-14. 
PWC. (2011). “Personalized medicine in European hospitals.” [derived on 15.03.2016 from 
http://www.hope.be/05eventsandpublications/docpublications/88_personalised_medicine/88_HOPE-
PWC_Publication-Personalised-Medicine_February_2012.pdf] 
Roden, D. M., et al. 2008. "Development of a large‐scale de‐identified DNA biobank to enable personalized 
medicine." Clinical Pharmacology & Therapeutics 84 (3): 362-369. 
Ross, J. S., and G. S. Ginsburg. 2002. "Integrating diagnostics and therapeutics: revolutionizing drug discovery 
and patient care." Drug Discovery Today 7 (16): 859-864. 
Ruano, G.. 2004. "Quo vadis personalized medicine?" Personalized Medicine 1 (1): 1-7. 
Savard, J. 2013. "Personalised medicine: a critique on the future of health care." Journal of Bioethical Inquiry 10 
(2): 197-203. 
Schleidgen, S., et al. 2013. "What is personalized medicine: sharpening a vague term based on a systematic 
literature review." BMC Medical Ethics 14: 55. 
Simmons, L. A., et al. 2012. "Personalized medicine is more than genomic medicine: confusion over 
terminology impedes progress towards personalized healthcare." Personalized Medicine 9 (1): 85-91. 
Sorich, M., and R. A. McKinnon. 2012. "Personalized medicine: potential, barriers and contemporary issues." 
Current Drug Metabolism 13 (7): 1000-1006. 
Stelzer, B., et al. 2015. "Combining the scenario technique with bibliometrics for technology foresight: The case 
of personalized medicine." Technological Forecasting and Social Change 98: 137-156. 
Swan, M. 2009. "Emerging patient-driven health care models: an examination of health social networks, 
consumer personalized medicine and quantified self-tracking." International Journal of Environmental Research 
and Public Health 6 (2): 492-525. 
Swan, M.. 2012. "Health 2050: The realization of personalized medicine through crowdsourcing, the quantified 
self, and the participatory biocitizen." Journal of Personalized Medicine 2 (3): 93-118. 
Teng, Kathryn. 2015. "A shift toward personalized healthcare: does the Affordable Care Act provide enough 
incentive for change?" Personalized Medicine 12 (3): 231-235. 
Tseng, M. M., and J. Jiao. 2001. ‘‘Mass customization.’’ In G. Salvendy (ed.) Handbook of Industrial 
Engineering. 3rd Edition, Chapter 25: 684–709, New York: John Wiley & Sons. 
Yang, Y. Tony, Elizabeth Wiley, and John Leppard. 2011. "Individualized medicine and pharmacogenomics: 
ethical, legal and policy challenges." Journal of Medicine and the Person 9 (2): 48-57. 
White, W. D., and S. Chao. 2014. U.S. Patent No. 8,799,023. Washington, DC: U.S. Patent and Trademark 






Article 3:  
Employee involvement in innovation activities in hospitals: how 
perception matters 
Paper submitted to: 
Health Services Management Research  
The following paper shows the initial submission to Health Services Management 








Employee involvement in innovation 
















All at Chair of Innovation Management and Entrepreneurship, HHL Leipzig Graduate School of Management, 
Jahnallee 59, 04109 Leipzig, Germany  
Employees are a very important source of innovation and essential for the generation, 
dissemination and implementation of these ideas throughout the organization. This is 
especially relevant when considering innovation in services during service (co-) creation such 
as within the healthcare sector. However, perceived employee involvement in innovation 
(EII) and between stakeholder group interactions in hospitals has not yet been studied in 
detail. This paper addresses the following research questions: (1) “How do different 
employee groups perceive their involvement in the innovation process and their interaction 
with other employee groups?” and (2) “How does this perception influence the innovation 
output?” We analyzed a single typical German research hospital and conducted episodic 
interviews with employees representing different staff groups.  
We revealed that while all groups of employees are involved in innovation activities, 
perception of their involvement in innovation activities differs widely between stakeholder 
groups, hierarchy levels and along the innovation management process. Further, their 
interaction and co-creation with each other and external stakeholders such as industry and 
patients differ widely as well. Both factors influence innovation output. With our paper, we 
add to the understanding of perceived EII in hospitals and discuss measures for hospital 
management to increase EII.   
 
1. Introduction  
The German healthcare system and its hospitals have undergone diverse reforms in the last 20 years. While cost 
containment has been improved, hospitals still struggle to meet the demands of patients, payers, and other 
stakeholders. Recent developments show changing customer / patient needs and demand for a more patient-
centered and value-based approach to healthcare
1
. Hospitals, as complex service organizations, engage various 
stakeholder groups and need to ensure their viability in a consolidating market while delivering the highest 
treatment quality within tight economic constraints and an institutionalized, bureaucratic environment. Thus, 
next to policy initiatives and reforms, innovation and the innovativeness reputation become more important for 
hospitals to cope with future challenges 
2
. 
It is widely accepted that employees are a very important group for innovation and value co-creation in a 
multi-stakeholder service environment 
3–5
. Thus, the topic of employee involvement in innovation (EII) has been 
extensively studied in the literature  
6,7
, and practices to foster innovative behavior amongst employees along the 





Current observations on EII in healthcare stem predominantly from medical technology and pharmaceutical 
companies 
8
. There have been continuous calls for research on the topic at the hospital level 
9
. So far, only few 
papers are concerned with the different stakeholder groups involved in innovation in hospitals and their 
interaction 
10
. Their focus lies on specialized groups such as nurses 
11
 , physicians 
12
 or on specific innovation 
activities (IA) such as R&D 
13
 and the implementation of medical innovations 
14
. To our knowledge, perceived 
involvement in innovation processes has not been studied extensively in the healthcare sector despite its 
importance for healthcare organizations 
15,16,6
. This poses an apparent gap in current research. Thus, this paper 
adds to the understanding the topic by answering the following research questions: (1) “How do different 
employee groups perceive their involvement in the innovation process and their interaction with other employee 
groups?” and (2) “How does this perception influence EII and innovation output?”. 
We conducted an in-depth case study of a typical German research hospital on perception EII and interaction 
in the innovation process. We add to the literature on EII in hospitals in the following respects: (a) we showcase 
a gap between perceived and actual involvement and interaction for different stakeholder groups within a 
hospital department, (b) we derive suggestions for hospital management to foster innovative behavior among 
employees, and, by using a typical case environment (c) we provide a benchmark case for management 
comparisons.  
2. Literature review  
Employee involvement has been defined as “the participation of the entire firm’s workforce to improve the 
working environment, product quality, equipment productivity, and eventually, company competitiveness”
17
 and 
is naturally linked to innovation. An employees’ perception of being involved impacts innovation success
15
. EII 
has received significant attention amongst researchers, which lead to a vast literature base drawing on social, 
behavioral as well as management sciences
18,4,19–21
. More recently, EII has gained traction in the services 
innovation literature with employees acting as value co-creators within the service delivery process. With close 
proximity to the customer, employees can provide in-depth insights on customer needs and opportunities for new 
services generation 
22
. Thus, EII provides significant opportunities for innovation in service-intensive 
environments such as hospitals.  
Applications of the research base on (perceived) EII to the specific case “hospital”, however, are increasing, 
but still rare. Thune and Mina
9
 argue that the hospital as a source for innovation is still under-researched and that 
IA are happening in a “black box”. Notable examples of research on the topic include: Djellal and Gallouj
23
 
deriving a framework for analyzing hospital innovation output, Salge and Vera
24
 focusing on the link between 
hospital innovation and hospital performance, Benzer et al.
25
 focusing on innovation and organizational change 
in hospitals, or Cucciniello et al.
26
 describing a health innovation implementation process. Existing literature on 
EII in healthcare rarely covers all employee groups, their perceived involvement in activities or their perceived 
interaction with one another (with the exception of 
10
), but rather focuses on physicians or nurses only 
11,12
.  
 As EII occurs through interaction of various groups, especially in a multi-stakeholder setting, we argue that 
the innovative potential of employees in hospitals has not been fully analyzed in the literature yet. Additionally, 
Thune and Mina
9
 suggest that the organizational capacity of hospitals and their employees to produce innovation 
is currently underemphasized in research. This is surprising as it is of high practical relevance of innovation for 
high-quality provision of medical services at reasonable cost. 
3. Research Design  
We conducted a qualitative single case study in order to get an in-depth understanding of the process and 
interactions under study 
27
. The sampling was theoretical and purposive. We found a typical German university-
linked research hospital, which can be contrasted with extreme cases, both positive and negative, in future 
research projects. After an initial literature review, we derived two research questions and a guideline for semi-
structured interviews. We performed episodic interviews in order to better understand EII and interactions within 
the innovation process. We combined the benefits of a semi-structured approach with the depth of information of 
a narrative and employ a method that is specifically useful for group comparisons, while also triangulating 







We prepared a list of stakeholder groups necessary to construct the case. These include: physicians, nurses, 
functional diagnostic staff, IT administration, medical technology management, laboratory staff, 
pharmacologists, central services, administrative staff, the medical director of a department and the economic 
director of a department. We contacted the head of a clinic department to discuss the project and to obtain ethical 
consent. We were provided with initial points of contact for the stakeholders on the list. Afterwards, we 
contacted the potential partners for interview appointments. 
Overall, we conducted 11 interviews, which lasted between 30 and 60 minutes. The interviews were 
conducted in German during a personal meeting or through a phone call. Following the interview, the 
researchers’ perception of the interview process was documented in a research note and the interviews were 
transcribed. We also collected data from publicly available sources such as the annual reports, press coverage 
and the hospitals website.    
All data was imported into MAXQDA and coded. The coding followed a qualitative content analysis procedure 
with deductive category application 
28
. Involvement was coded based on Shadur et al.
15
 Main and subcategories 
for involvement and interaction levels, stakeholder groups and steps of the innovation process were defined. The 
definitions, examples and coding rules were collected in a coding agenda and revised before final coding of the 
material and interpretation of the results. An excerpt of the coding agenda can be found in Appendix 1. 
4. Results 

























All respondents agreed on the importance of innovation and stated that they were motivated to try new things. A 
nurse said “I am open for everything, so if someone has a new idea that provides a benefit, I am very happy to 
look at it. I would never say ‘This does not make sense, leave it as it is’ right from the start.”
1
 While all groups of 
employees are involved in the innovation process to a certain extent, the perception of their involvement in IA 
differs immensely between employee groups and between hierarchy levels (Figure 1). 
                                                     
 
1
 As the interviews were conducted in German, all quotes mentioned in this paper were translated into English.  






Physicians reported high involvement levels, such as “as chief resident I am critically involved [in IA]”, while 
another physician described optimizing the patient management process in an outpatient clinic and further stated 
multiple joint research projects that he takes part in. Other groups with a perception of high involvement include 
researchers, pharmacology staff, laboratory staff as well as the IT department.  On the other hand, nursing staff, 
functional diagnostic staff, the commercial director or members of the administrative staff seem to perceive only 
limited or no involvement in multiple phases. A nurse stated: “Especially such small things, where a nurse would 
be asked: ‘What would you improve?’ — that is not done often enough”. 
 
High perceived EII is linked to a high position within the hierarchy. This was acknowledged by most 
participants, with an anesthesiologist stating: “I think this is because I am, let’s say, further up in the hierarchy, 
so that if I have a good idea, I know who I need [to pursue it] and which network I have to create by myself to 
implement it.” The Head of Pharmacology stated “100 percent, this is my job”, while the Head of IT said that 
“We are always involved, because almost nothing works without IT support anymore.” The Head of Laboratory 
stated “[My involvement] is very high, which even leads to some suffering […] as a lot of innovation [means] a 
lot of change. On the other hand, regular employees and even middle management, especially within the nursing 
and administrative departments recount no or only very little involvement without prompting.  Nurses said: “I 
think, the lower you are in the hierarchy, the less you are involved and the less you are consulted.” and “We are 
generally not involved in the idea process.”  Interestingly, when prompted about specific IA such as talking 
about potential process improvements with colleagues, taking part in training on innovative technology or taking 
part in research projects, even participants who had previously stated no involvement were able to recount an 
episode from their daily work that showcased at least low levels of involvement. A nurse said in this regard 
“Those were not really my ideas, but rather suggestions how we can transfer processes from others, that are more 
modern, to our department.” Some even exhibited high involvement e.g. within research projects such as a nurse 
working directly on project to improve oral care. She stated “[A doctor] was very engaged and worked with me, 
because I [work with] the patient group.”    
 
Finally, as portrayed in Figure 1, perceived involvement levels also differ along phases of the innovation 
process. While the IT and the laboratory departments recount high perceived levels of involvement throughout 
the whole process, other department stakeholders perceive their involvement being tied to certain phases of the 
process. The department for medical technology reported to be mainly involved in testing and implementation of 
innovation, with the Head of the department saying “We are integrated in the process. Certainly not in the 
primary phase, but rather in the secondary phase” and “Yes, we are involved, but the idea does not come from 
us.” The administrative staff perceived their involvement to mainly happen within the idea selection stage by 
contributing through e.g. cost-benefit analyses or market analyses, with a respondent stating “We do a cost-
benefit analysis, calculate the cases, the profits, the costs.” Interestingly, an upper management level 
anesthesiologist reported that “[Within the administrative staff] there are a lot of people, whose main goal is not 
to innovate, best case they tolerate it”. Nurses and lower level administrative staff perceive no involvement in the 
early stages of the innovation process, even though they are able to recount episodes that clearly point to 
involvement, such as developing ideas and communicating them to their superiors.  
 
Overall, staff perceiving high EII appears very active in their pursuit of implementation through forming 
networks of support or engaging with other stakeholders to push the desired project, leading to a positive 
influence on innovation output. Staff levels with no or very low levels of perceived EII frequently reported 
obstacles to innovation, often linked to the phase of idea generation and idea selection. A nurse said “We have 
this suggestion system. But I have never used it, because I do not know what happens to my idea.” They often 
report a lack of motivation to participate in IA due to a high workload, a lack of time, no or negative feedback in 
the past or lack of management support. This in turn negatively impacts innovation output.  
 
4.2 (Perceived) Interaction between stakeholder groups along the innovation process  
All respondents highlighted the importance of interaction and collaboration between the different employee 
groups to create and implement innovations. The Head of Pharmacology stated in that regard: “Without 






Perceived interaction, however, differed widely amongst the stakeholder groups, hierarchy levels and phases of 
the innovation management process. The Head of Pharmacology underlined this by stating: “We are ahead when 
it comes to interdisciplinarity in medicine. However, this ends with the physician. If they [were to] start to take 
other groups more seriously, not just formally, but really seriously — but we are not there yet.” Physicians 
reported interactions with functional diagnostic staff and nursing staff, such as an anesthesiologist who stated 
“Chemists and physicians [working on the proposal], during implementation functional diagnostic staff will be 
involved” and when asked about another project: “Physicians and outpatient clinic staff. This is mainly nursing 
staff. [..] oh yes. And the IT department.” The medical technology department reported interactions with 
“Nursing staff for sure. The functional diagnostics staff, the pathology department and the laboratory department 
[…] and the IT department of course.” This indicates high perceived interaction with a multitude of stakeholder 
groups. However, another physician stated: “Mainly with doctors […] not with nursing staff at all. Not in this 
aspect” and “Well, it is hard to get connected to the right people. Sometimes I feel like there is not a lot of 
cooperation within the university. And sometimes, there are colleagues that define themselves through 
dissociation. […] they just take an [idea for an] innovation opportunity from you and do it themselves, rather 
than cooperating.” The administrative staff reported low interaction levels with other groups, indicating that they 
mainly follow established feedback protocols, while the upper management of the administrative department 
mainly interacts with physicians, the IT department and external partners.  
 
Respondents of the nursing staff mainly reported low levels of interactions (often one-off) and mainly with 
physicians. Interestingly, they attributed it to their standing in the hierarchy. A nurse stated “It is difficult, 
because [it is] such a hierarchically organized company with no intention of reducing hierarchies”. Another 
nurse recounted an episode of a task force: “I think [the medical director] was more of an autocratic decision 
maker. I do not know how far it could be considered an equal task force.” Interestingly, EII of nursing staff is 
sometimes overlooked by other stakeholders and hierarchy levels. An anesthesiologist stated: “I would not make 
a big fuss about it. If it comes to fine tuning and process improvement, of course we talk every day. No question. 
And for the recovery room […] we talked with the middle management nursing staff, because they are directly 
involved.” The Head of Laboratory recounted: “Well no. We have a lot of contact, but not about the topic 
[innovation]. Actually, we do interact with all stakeholder groups. If we talk about innovation in transporting 
samples, we talk with nursing staff, because they are more involved.” 
 
Finally, perceived interaction differs along the stages of the innovation process. Idea generation often occurs 
within a stakeholder group rather than following a joint ideation process. A nurse said “I talked to my colleagues 
about [my idea] and they said ‘do it, it is a very good idea”. The Head of Medical Technology said “Firstly 
within my department and then, if there is friends from other departments I may talk with them.” A notable 
exception is the pharmacology department as the Head mentioned a joint ideation effort together with 
physicians, IT and the Board in order to draft a proposal for an innovation fund. Several department heads 
mentioned cooperation with industry in the idea stage. Interestingly, collaboration and co-creation with patients 
as external partners was only mentioned by nursing staff. One nurse stated: “This was not a big idea we 
implemented, but rather the patients and their families demanded it and we complied with the request over time.” 
Interaction within the idea selection and innovation design stage depends on the type of innovation. With 
incremental innovation, there is usually within-group communication, often with undesired outcomes. A nurse 
reflected: “If you try to improve something for the ward, my ideas are always nipped in the bud or my ideas were 
not good enough.” For more radical innovations, the idea selection stage involves high levels of management 
interaction as projects often need to be approved by multiple department heads and the Board, sometimes leading 
to long delays of the process. A physician stated “There is an idea that was communicated to the Board, to the IT 
department, to external partners, to the health ministry […] everybody is excited, but nothing happens.” 
Interestingly, he also stated “Everybody is wary of the others. If you have a good idea, someone will just come 
and steal it. This culture inhibits fruitful interactions.” High levels of interaction are perceived in the testing and 
implementation stage. Physicians, nurses and functional diagnostics staff recount being involved in clinical trials 
or research projects, often with external partners such as industry or other research institutions. A nurse stated: 
“We treat patients according to clinical trial protocols.” The implementation of innovation is often linked to 
training and with that interaction with other stakeholder groups, with a nurse stating “I am trained on every new 
technology”, indicating an interaction with the medical technology and IT department staff.  
Overall, staff with a perceived high involvement in innovation also tends to report high interaction levels with 





5. Discussion and implications  
5.1 Strict hierarchy levels, physician centricity and high workload limit EII of certain 
stakeholder groups in hospitals. 
EII differs amongst the different stakeholder groups of a hospital department. Employees in management 
positions are more likely to classify IA as innovations, while employees lower in the hierarchy, especially within 
nursing, functional diagnostics or administrative staff often see their activities as part of their jobs and not 
particularly innovative. Respondents on all hierarchy levels mentioned that they see a need for cultural change 
and opening up the strict hierarchies and diverge from the physician-centricity still prevailing in the hospital 
culture. Next to a high workload and low levels of freedom for creativity, lower level employees often 
mentioned a lack of management support which is in line with O’Donoghue et al.
29
 This observation is in line 
with the hierarchical and physician-centric structure of a research hospital. Cultural change may provide a 
positive impact on the individual’s readiness for change and innovation and foster individual engagement
25
 
Further, digitalization of the hospital may lead to more democratization and decentralization of the innovation 
process. However, the implementation must be done thoughtfully and communicated thoroughly, as indicated by 
the example of the digital suggestion system in our case. Since there is no transparency about the process, 
respondents prefer personal interaction within their network over submitting a suggestion into the system.  
5.2 There is a significant gap between perceived involvement and actual involvement in 
innovation activities, which lowers employee motivation and inhibits innovation output.  
While it seems that all employees are contributing to IA, albeit to varying degrees, and within different stages of 
the innovation process, not all perceive their contribution as actual involvement. This is particularly the case for 
nursing, functional diagnostic or administrative staff — staff that directly interacts with the patient in front-line 
service provision. Given the importance of (service) co-creation in service intensive environments 
4
 this suggests 
a lot of untapped potential for hospitals in their search for improving patient care and internal processes. By 
empowering (front-line) employees and helping them recognize that their actions are actively contributing to 
innovation and improvement, management could leverage this potential to provide more tailored and more 
efficient patient care. Concrete measures could include: training staff on the basics of idea creation and idea 
management
30
, providing a transparent suggestion and feedback system or facilitating systematic ideation 
workshops or think tanks, as suggested by a participant from the nursing staff. These think tanks should include 
participants from all stakeholder groups and emphasize an open culture, where hierarchy is not important and all 
participants are able to speak and interact freely without fear of negative repercussions. These measures would 
increase the perceived involvement, especially in the idea creation and idea selection phase, leading to more 
potentially fruitful ideas entering the innovation management process. The implementation of such measures, 
however, demands a move towards a more innovation-friendly culture. Our results suggest that the perception of 
EII and the overall involvement of the peer group in the hospital have an impact on employees’ willingness to 





in a healthcare setting. When employees perceive that they are not involved in IA or that their ideas are not 
worth to even be discussed, such as mentioned e.g. by nursing staff, they often keep ideas to themselves or even 
try to interfere with ideas of others as indicated by physicians.  
5.3 Pursuing an open innovation approach and increasing perceived hierarchy-independent 
interaction with internal and external stakeholder groups may increase innovation output 
Our results show that between-group interaction is limited along the innovation process — notable exemptions 
being the joint ideation for large research projects at management level and some interaction within the 
implementation phase. This is not surprising given the hierarchical nature of the hospital and perceived mistrust 
amongst staff members. As internal supporting networks are very important for innovation 
7
, this poses a clear 
barrier to successful IA. There is a need for organizational and cultural change. Recognizing and communicating 
the potential and importance of all groups regardless of their standing within the hierarchy for their contributions 
to the innovation process may be a first step to empowerment. Furthermore, an investment in communication 





collaborate in other phases. Interestingly, while a lot of respondents report interactions with industry, other 
researchers or hospitals, only members of the nursing staff report interaction and co-creation with patients. 
However, research has shown that co-creation with users, especially within service environments, can lead to 
significant improvements
1
. Hence, management should consider implementing open innovation approaches such 
as joint ideation activities and frequently ask for ideas from front-line employees.  
 
Overall, our data shows that there is untapped potential for innovative ideas within certain groups of hospital 
staff. Management may be particularly interested in the results of this study, as these ideas may have the 
potential to reduce costs and provide better patient care. It is important to know who perceives to be involved in 
the innovation process and who interacts with whom. Management should create a common understanding and 
awareness for all types of innovation by providing training for all staff groups on the importance of this topic 
and aim to increase the innovation awareness, involvement, interaction and output by the hospital staff in order 
to achieve the overarching goal of providing the best possible patient care.  
6. Limitations and opportunities for further research 
We conducted a single exploratory case study; our findings are limited to a specific setting. The gathered data is 
subjective to the respondent. We aim to counter this by using episodic interviews and triangulating with publicly 
available sources. For further research, it would be interesting to conduct a multiple case study using the present 
case as a base case within a national setting. Measuring and comparing the innovation output of hospitals that are 
implementing EII initiatives before and after implementation may also lead to informative results for 
management. We explored EII in a large public research hospital. Contrasting privately owned hospitals may 
further add to the understanding of EII. Unfortunately, we were not allowed to shadow our interview 
respondents, which would have allowed for a more objective assessment of real vs. perceived involvement.  
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